Symptom-centric view

Accidental exposure to product

Substances reporting Accidental exposure to product disproportionately — ranked by ROR.

showing 21 of 21

Substance ↓	ROR [95% CI]	Reports	Category	Label
tezepelumab-ekko —	2.3 [1.8–3.0]	61	algemeen	new
somatropin Genotropin · Humatrope	3.0 [2.8–3.2]	971	hormones	new
pegfilgrastim —	12.0 [11.7–12.4]	5,033	algemeen	new
ofatumumab —	6.3 [5.9–6.7]	915	algemeen	new
mepolizumab —	7.6 [7.2–8.0]	1,620	algemeen	new
lotilaner ophthalmic solution —	4.9 [3.8–6.4]	56	algemeen	new
insulin glargine and lixisenatide —	21.4 [19.0–24.0]	309	algemeen	new
guselkumab —	24.8 [23.9–25.7]	3,315	algemeen	new
fremanezumab-vfrm —	32.9 [31.1–34.8]	1,438	algemeen	new
evolocumab —	30.3 [29.7–30.8]	16,450	algemeen	new
erenumab-aooe —	55.5 [54.2–56.7]	10,103	algemeen	new
dupilumab —	7.7 [7.5–7.8]	13,305	algemeen	new
brimonidine tartrate, timolol maleate —	5.3 [4.5–6.2]	157	algemeen	new
brimonidine tartrate —	2.4 [2.2–2.7]	311	algemeen	new
brimonidine —	2.4 [2.2–2.7]	311	algemeen	new
blinatumomab —	4.3 [3.7–4.9]	197	algemeen	new
bevacizumab-awwb —	4.3 [3.5–5.3]	89	algemeen	new
belimumab —	6.9 [6.5–7.4]	954	algemeen	new
beclomethasone dipropionate hfa —	3.1 [2.3–4.3]	39	algemeen	new
bacillus calmette-guerin —	5.7 [4.2–7.6]	45	algemeen	new
acetaminophen and dextromethorphan hydrobromide —	2.9 [2.4–3.7]	84	algemeen	new

ROR = reporting odds ratio vs. the full FAERS corpus. A signal is not a cause. Source: openFDA (FAERS).